Advertisement
GlaxoSmithKline
Subscribe to GlaxoSmithKline

The Lead

Lack of a MERS vaccine frustrates scientists

June 18, 2015 12:28 pm | by Kate Kelland and Ben Hirschler, Reuters | News | Comments

Three years after the mysterious MERS virus first emerged in humans, scientists and drugmakers say there is no excuse for not having a vaccine that could have protected those now falling sick and dying in South Korea. The facts behind the coronavirus ...

Perrigo to acquire GSK OTC brands

June 2, 2015 12:27 pm | by PR Newswire | News | Comments

Perrigo will acquire a portfolio of well-established over-the-counter brands from...

Glaxo Recalls Flu Vaccine Due to Potency Problem

April 17, 2015 3:37 pm | by MATTHEW PERRONE, AP Health Writer | News | Comments

The company alerted U.S. customers Tuesday that the vaccine can lose potency and fail to...

FDA Panel Backs Glaxo Inhaler for Adults, Not Adolescents

March 20, 2015 8:39 am | by MATTHEW PERRONE, AP Health Writer | News | Comments

Government health advisers say a once-a-day respiratory inhaler from GlaxoSmithKline appears...

View Sample

FREE Email Newsletter

GSK Completes Sale of Half Its Stake in Aspen Pharmacare

March 13, 2015 8:36 am | News | Comments

GlaxoSmithKline has announced the completion of the disposal of half of its 12.4% shareholding in Aspen. Following settlement of the sale, GSK will hold 28.2 million ordinary shares in Aspen, representing approximately 6.2% of the issued share capital.

Sun Pharma to Buy GSK’s Opiates Business in Australia

March 3, 2015 9:05 am | News | Comments

The current GSK Opiates business including related manufacturing sites in Latrobe (Tasmania) and Port Fairy (Victoria) and its portfolio of opiates products along with inventory, will transfer to a subsidiary of Sun Pharma.

GSK Completes Transaction with Novartis

March 2, 2015 3:48 pm | News | Comments

Britain's GlaxoSmithKline PLC and Switzerland's Novartis AG have completed a three-part deal that will offer the British company's shareholders a 4 billion pound ($6.17 billion) windfall.

Advertisement

Survey: Clinical Trial Sponsors Show Improvement

March 2, 2015 11:19 am | by Andy Szal, Digital Reporter | News | Comments

Pharmaceutical companies sponsoring clinical trials showed strong improvement in their relationships with global investigative sites, according a recent survey.

GSK's Nonprescription Diet Pill Back in Stores After Recall

February 25, 2015 8:08 am | by The Associated Press | News | Comments

GSK voluntary recalled Alli last March after finding some packages in stores didn't contain real alli, indicating tampering after shipment. The Food and Drug Administration is still investigating.

GSK Acquires GlycoVaxyn for $212M

February 11, 2015 8:36 am | News | Comments

Edmond de Rothschild Investment Partners announced today that its BioDiscovery 3 portfolio company, GlycoVaxyn AG, a privately held specialist vaccine biopharmaceutical company, has been acquired by GlaxoSmithKline in an all-cash transaction valuing the company at approximately $212M.

GlobalData Analyst: GlaxoSmithKline Encounters Initial Resistance Following Directional Shift

February 10, 2015 1:22 pm | News | Comments

Following a less than flattering financial performance in 2014, GlaxoSmithKline is realigning its operating structure with its corporate objectives and cashing in on its assets in the process, as the company seeks to drive up external investments and deliver stronger shareholder returns in the long term, says an analyst with research and consulting firm GlobalData.

GSK Expands Its Asthma and COPD Portfolio in the US

January 26, 2015 10:36 am | News | Comments

GlaxoSmithKline has announced the simultaneous availability of two of its recently approved products for the treatment of asthma and COPD to retail pharmacies in the US. Over the past 15 months, GSK has launched four inhaled respiratory therapies in the US, all delivered in its Ellipta inhaler.

Advertisement

Array BioPharm to Acquire Novartis’ Encorafenib

January 23, 2015 8:23 am | News | Comments

Array BioPharma today announced that it has reached a definitive agreement with Novartis Pharma AG to acquire worldwide rights to encorafenib (LGX818), a BRAF inhibitor currently in Phase 3 development.        

Two Leading Ebola Vaccines Appear Safe, Further Tests Starting

January 9, 2015 8:14 am | by MARIA CHENG, AP Medical Writer | News | Comments

After an expert meeting this week, WHO said there is now enough information to conclude that the two most advanced Ebola vaccines — one made by GlaxoSmithKline and the other licensed by Merck and NewLink — have "an acceptable safety profile."  

Roivant Acquires SB742457 from GlaxoSmithKline

December 29, 2014 2:42 pm | News | Comments

Roivant Neurosciences has entered into an agreement with GlaxoSmithKline for the acquisition of SB742457, a selective 5-HT6 receptor antagonist with the potential to improve cognition and function in multiple central nervous system disorders.  

GSK Reports Positive Outcome of Phase III Study of Shingles Vaccine Containing Agenus Adjuvant

December 18, 2014 10:58 am | News | Comments

Agenus and its partner GlaxoSmithKline have reported that the ZOE-50 Phase III study met its primary endpoint. Analysis of the primary endpoint showed that HZ/su reduced the risk of shingles by 97.2% in adults aged 50 years and older compared to placebo.

GlaxoSmithKline Announces 900 Layoffs

December 4, 2014 8:37 am | Videos | Comments

GlaxoSmithKline released details of a restructuring program Wednesday, which included 900 layoffs.                          

Advertisement

Clovis Oncology and GSK to Collaborate on Oncology Clinical Trial

November 18, 2014 8:12 am | News | Comments

Clovis Oncology has entered into a clinical trial collaboration with GlaxoSmithKline to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC).      

EMA Advises on Development Plan for GSK Ebola Vaccine

October 29, 2014 11:15 am | News | Comments

The European Medicines Agency (EMA) has given scientific advice to GSK on its development plan for an Ebola vaccine. This is the first time in the current Ebola outbreak that EMA has given ‘rapid scientific advice’ using an accelerated procedure.

Swissmedic Approves Trial for Ebola Vaccine

October 28, 2014 7:35 am | by The Associated Press | News | Comments

The Swiss agency that regulates new drugs has approved an application for a clinical trial with an experimental Ebola vaccine at the Lausanne University Hospital. Swissmedic said the trial will be conducted among 120 volunteer participants with support from the U.N. World Health Organization.

GlaxoSmithKline Third Quarter 2014 Results Interview with CEO Sir Andrew Witty & CFO Simon Dingemans.

October 27, 2014 9:07 am | Videos | Comments

Interview with Sir Andrew Witty, CEO, and Simon Dingemans, CFO announcing the company's Q3 2014 results including a restructuring of the business and a possible partial IPO of ViiV Healthcare.          

Drugmakers Bet on Ebola Vaccines, Treatments

October 26, 2014 9:33 am | by Matthew Perrone - Associated Press - Associated Press | News | Comments

Drugmakers are racing to develop vaccines and drugs to address the worst outbreak of Ebola in history. It's unclear who will pay for their products, but companies are betting that governments and aid groups will foot the bill.    

WHO: Millions of Ebola Vaccine Doses Ready in 2015

October 24, 2014 11:38 am | by Maria Cheng - AP Medical Writer - Associated Press | News | Comments

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March. Still, the agency warned it's not clear whether any of these will work against the deadly virus that has...

Isis Pharmaceuticals Earns $18M From GSK for Advancing ISIS-TTR Rx

October 9, 2014 8:14 am | News | Comments

ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.  Including this $18M milestone payment, Isis has generated $45M of the $70M in upfront and milestone payments Isis is eligible to earn for advancing ISIS-TTRRx in development.

Novartis Says Three Members of Executive Committee to Leave Company

October 8, 2014 9:09 am | News | Comments

Novartis confirmed today that following completion of the transactions with GlaxoSmithKline and Eli Lilly and Company in the coming months, that the three business leaders of the Novartis divisions at the center of the transaction will leave the Executive Committee of Novartis.

Drug Firms Redirect Sales Pitch to Hospitals

October 3, 2014 8:40 am | Videos | Comments

Pharmaceutical companies are refining their sales strategy. GlaxoSmithKline's Dierdre Connelly discusses why with WSJ's Tanya Rivero.                    

Experimental Ebola Vaccine Processed in Maryland

October 2, 2014 10:48 am | News | Comments

The National Institute of Allergy and Infectious Diseases says an experimental Ebola vaccine is being processed at a facility in Frederick. The vaccine is a joint project between the federal agency and GlaxoSmithKline.      

GE Healthcare to Collaborate with GlaxoSmithKline on Commercial Oncology Testing

October 1, 2014 8:35 am | News | Comments

The collaboration aims to improve access to diagnostic testing for cancer patients by establishing a network of clinical laboratories to identify genetic mutations associated with different tumor types.        

Analyst: GSK's $490M Fine to Spark Pharma Strategy Shift in Emerging Markets

September 24, 2014 11:21 am | News | Comments

The scandal and its repercussions will be felt deep into Big Pharma’s operations in emerging markets, causing a fundamental shift in product marketing approaches involving physicians.           

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading